热景生物
(688068)
| 流通市值：99.21亿 | | | 总市值：99.21亿 |
| 流通股本：9247.47万 | | | 总股本：9247.47万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 386,162,937.71 | 248,810,028.12 | 116,124,860.44 | 541,251,205.97 |
| 营业收入 | 386,162,937.71 | 248,810,028.12 | 116,124,860.44 | 541,251,205.97 |
| 二、营业总成本 | 444,863,278.09 | 295,455,665.46 | 123,890,515.38 | 589,237,493.62 |
| 营业成本 | 183,673,367.75 | 124,464,867.46 | 47,567,259.59 | 232,994,996.71 |
| 税金及附加 | 4,117,913.46 | 3,014,038.79 | 877,301.32 | 4,688,384.81 |
| 销售费用 | 129,084,145.72 | 90,903,061 | 38,573,495.92 | 171,153,585.54 |
| 管理费用 | 70,854,336.71 | 42,295,082.11 | 22,005,975.53 | 91,734,458.55 |
| 研发费用 | 77,198,837.52 | 49,646,684.94 | 22,667,361.22 | 131,447,368.91 |
| 财务费用 | -20,065,323.07 | -14,868,068.84 | -7,800,878.2 | -42,781,300.9 |
| 其中:利息费用 | - | 173,092.79 | - | 1,008,798.69 |
| 其中:利息收入 | 20,005,113.82 | 15,151,387.57 | 7,974,995.44 | 39,587,026.49 |
| 加:公允价值变动收益 | 19,700,082.57 | -2,867,291.23 | 14,864,529.05 | -5,154,677.61 |
| 加:投资收益 | -9,402,109.95 | 2,901,208.51 | -5,182,455.32 | -17,159,387.06 |
| 资产处置收益 | 1,162,986.74 | 284,632.87 | 1,752,079.42 | -642,723.74 |
| 资产减值损失(新) | -99,632.54 | -545,958.43 | - | -11,613,584.87 |
| 信用减值损失(新) | -2,121,326.21 | -4,039,056.53 | - | 12,096,896.34 |
| 其他收益 | 11,167,725.74 | 8,848,265.47 | 1,776,703.3 | 87,670,096.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -38,292,614.03 | -42,063,836.68 | 5,445,201.51 | 17,210,331.56 |
| 加:营业外收入 | 1,647,206.51 | 171,744.96 | 78,676.47 | 2,597,470.65 |
| 减:营业外支出 | 1,206,049.78 | 1,180,379.07 | 420,715 | 6,302,828.57 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -37,851,457.3 | -43,072,470.79 | 5,103,162.98 | 13,504,973.64 |
| 减:所得税费用 | 4,829,939.31 | 2,590,124.57 | 1,572,353.86 | -1,548,890.57 |
| 六、净利润 | -42,681,396.61 | -45,662,595.36 | 3,530,809.12 | 15,053,864.21 |
| 持续经营净利润 | -42,681,396.61 | -45,662,595.36 | 3,530,809.12 | - |
| 归属于母公司股东的净利润 | -40,638,579.96 | -43,467,813.74 | 5,054,819.8 | 27,382,940.5 |
| 少数股东损益 | -2,042,816.65 | -2,194,781.62 | -1,524,010.68 | -12,329,076.29 |
| (一)基本每股收益 | -0.44 | -0.47 | 0.06 | 0.31 |
| (二)稀释每股收益 | -0.44 | -0.47 | 0.06 | 0.31 |
| 八、其他综合收益 | 439,023.3 | -221,523.36 | - | -86,482.81 |
| 归属于母公司股东的其他综合收益 | 439,433.91 | -221,112.76 | - | -83,190.33 |
| 九、综合收益总额 | -42,242,373.31 | -45,884,118.72 | 3,530,809.12 | 14,967,381.4 |
| 归属于母公司股东的综合收益总额 | -40,199,146.05 | -43,688,926.5 | 5,054,819.8 | 27,299,750.17 |
| 归属于少数股东的综合收益总额 | -2,043,227.26 | -2,195,192.22 | -1,524,010.68 | -12,332,368.77 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |